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AbstrAct
•	 Objective:	To	review	the	adverse	drug	events	(ADEs)	
risk	 of	 polypharmacy;	 the	 process	 of	 deprescribing	
and	 evidence	 of	 efficacy	 in	 reducing	 inappropriate	
polypharmacy;	 the	 enablers	 and	 barriers	 to	 depre-
scribing;	and	patient	and	system	of	care	level	strate-
gies	that	can	be	employed	to	enhance	deprescribing.
•	 Methods:	Literature	review.
•	 Results:	 Inappropriate	 polypharmacy,	 especially	 in	
older	people,	imposes	a	significant	burden	of	ADEs,	
ill	 health,	 disability,	 hospitalization	 and	 even	 death.	
The	 single	 most	 important	 predictor	 of	 inappropri-
ate	prescribing	and	risk	of	ADEs	in	older	patients	 is	
the	 number	 of	 prescribed	medicines.	 Deprescribing	
is	 the	 process	 of	 systematically	 reviewing,	 identify-
ing,	and	discontinuing	potentially	inappropriate	medi-
cines	(PIMs),	aimed	at	minimizing	polypharmacy	and	
improving	patient	outcomes.	Evidence	of	efficacy	for	
deprescribing	is	emerging	from	randomized	trials	and	
observational	 studies,	 and	 deprescribing	 protocols	
have	been	developed	and	 validated	 for	 clinical	 use.	
Barriers	and	enablers	 to	deprescribing	by	 individual	
prescribers	 center	 on	 4	 themes:	 (1)	 raising	 aware-
ness	of	 the	prevalence	and	characteristics	of	PIMs;	
(2)	overcoming	clinical	 inertia	whereby	discontinuing	
medicines	 is	seen	as	being	a	 low	value	proposition	
compared	to	maintaining	the	status	quo;	(3)	increas-
ing	 skills	 and	 competence	 (self-efficacy)	 in	 depre-
scribing;	 and	 (4)	 countering	 external	 and	 logistical	
factors	that	impede	the	process.	
•	 Conclusion:	 In	 optimizing	 the	 scale	 and	 effects	 of	
deprescribing	 in	clinical	practice,	strategies	that	pro-
mote	depresribing	will	need	to	be	applied	at	both	the	
level	of	 individual	patient–prescriber	encounters	and	
systems	of	care.	
In developed countries in the modern era, about 30% of patients aged 65 years or older are prescribed 5 or more medicines [1]. Over the past decade, the preva-
lence of polypharmacy (use of > 5 prescription drugs) in 
the adult population of the United States has doubled 
from 8.2% in 1999–2000 to 15% in 2011–2012 [2]. 
While many patients may benefit from such polyphar-
macy [3] (defined here as 5 or more regularly prescribed 
medicines), it comes with increased risk of adverse drug 
events (ADEs) in older people [4] due to physiological 
changes of aging that alter pharmacokinetic and pharma-
codynamic responses to medicines [5]. Approximately 
1 in 5 medicines commonly used in older people may 
be inappropriate [6], rising to a third among those liv-
ing in residential aged care facilities [7]. Among nursing 
home residents with advanced dementia, more than half 
receive at least 1 medicine with questionable benefit [8]. 
Approximately 50% of hospitalized nursing home or 
ambulatory care patients receive 1 or more unnecessary 
medicines [9]. Observational studies have documented 
ADEs in at least 15% of older patients, contributing to 
ill health [10], disability [11], hospitalization [12] and 
readmissions [13], increased length of stay, and, in some 
cases, death [14]. This high level of iatrogenic harm from 
potentially inappropriate medicines (PIMs) mandates 
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a response from clinicians responsible for managing 
medicines. 
In this narrative review, we aim to detail the ADE risk 
of polypharmacy, the process of deprescribing and evi-
dence of its efficacy in reducing potentially inappropriate 
polypharmacy, the enablers and barriers to deprescribing, 
and patient and system of care level strategies that can be 
employed in enhancing deprescribing. 
Polypharmacy As a risk Factor for 
Medicine-related Harm
The number of medicines a patient is taking is the single 
most important predictor of medicine-related harm 
[15]. One report estimated the risk of ADEs as a con-
tributory cause of patients presenting acutely to hospital 
emergency departments to be 13% for 2 drugs, 38% for 
4 drugs, and 82% for 7 drugs or more [16]. The more 
medicines an individual takes, the greater their risk of 
experiencing an adverse drug reaction, a drug-drug 
interaction, a drug-disease interaction, cascade prescrib-
ing (where more medicines are added to counteract side 
effects of existing medicines), nonadherence, and drug 
errors (wrong drug, wrong dose, missed doses, errone-
ous dosing frequency) [17–20]. Once the number of 
regular medicines rises above 5 (commonly regarded 
as the threshold for defining polypharmacy), observa-
tional data suggest that additional medicines indepen-
dently increase the risk of frailty, falling, and hospital 
admission [21]. 
The benefits of many medicines in frail older people 
remain unquantified. As many as 50% of clinical trials 
have a specific upper age limit and approximately 80% of 
clinical trials exclude people with comorbidities [22,23]. 
Single-disease treatment guidelines based on such trials 
are often extrapolated to older people with multimor-
bidity despite an absence of evidence for benefit [24] and 
with little consideration of the potential burdens and 
harms of polypharmacy resulting from treating multiple 
diseases in the one patient [25]. By contrast, the risks 
from many medicines in older people are well known. 
Older people are at high risk of ADEs and toxicity due to 
reduced renal and liver function and age-related changes 
in physiological reserve, body composition, and cellular 
metabolism [26]. While the adverse effects of polyphar-
macy or of comorbidities targeted for treatment are diffi-
cult to separate, the burden of medicine-induced decline 
in function and quality of life is becoming better defined 
and appreciated [27]. 
Defining Evidence-based Deprescribing
While many definitions have been proposed [28], we 
define evidence-based deprescribing as follows: the active 
process of systematically reviewing medicines being used 
by individual patients and, using best available evidence, 
identifying and discontinuing those associated with 
unfavorable risk–benefit trade-offs within the context 
of illness severity, advanced age, multi-morbidity, physical 
and emotional capacity, life expectancy, care goals, and 
personal preferences [29]. An enlarging body of research 
has demonstrated the feasibility, safety and patient benefit 
of deprescribing, as discussed further below. It employs 
evidence-based frameworks that assist the prescriber [30] 
and are patient-centered [31]. 
Importantly, deprescribing should be seen as part of 
the good prescribing continuum, which spans medicine 
initiation, titrating, changing, or adding medicines, and 
switching or ceasing medicines. Deprescribing is not 
about denying effective treatment to eligible patients. It 
is a positive, patient-centered intervention, with inher-
ent uncertainties, and requires shared decision-making, 
informed patient consent and close monitoring of effects 
[32]. Deprescribing involves diagnosing a problem (use 
of a PIM), making a therapeutic decision (withdrawing 
it with close follow-up) and altering the natural history 
of the problem (reducing incidence of medicine-related 
adverse events). 
Our definition of evidence-based deprescribing is a 
form of direct deprescribing applied at the level of the 
individual patient-prescriber/pharmacist encounter. 
Direct deprescribing uses explicit, systematic processes 
(such as using an algorithm or structured deprescribing 
framework or guide) applied by individual prescribers 
(or pharmacists) to the medicine regimens of individual 
patients (ie, at the patient level), and which targets either 
specific classes of medicines or all medicines that are 
potentially inappropriate. This is in contrast to indirect 
deprescribing, which uses more generic, programmatic 
strategies aimed at prescribers as a whole (ie, at the popula-
tion or system level) and which seek to improve quality use 
of medicines in general, including both underuse and over-
use of medicines. Indirect deprescribing entails a broader 
aim of medicines optimization in which deprescribing 
is a possible outcome but not necessarily the sole focus. 
Such strategies include pharmacist or physician medicine 
reviews, education programs for clinicians and/or patients, 
academic detailing, audit and feedback, geriatric assess-
ment, multidisciplinary teams, prescribing restrictions, 
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and government policies, all of which aim to reduce the 
overall burden of PIMs among broad groups of patients. 
While intuitively the 2 approaches in combination should 
exert synergistic effects superior to those of either by itself, 
this has not been studied. 
Evidence For Deprescribing
Indirect Deprescribing 
Overall, the research into indirect interventions has been 
highly heterogenous in terms of interventions and mea-
sures of medicine use. Research has often been of low to 
moderate quality, focused more on changes to prescribing 
patterns and less on clinical outcomes, been of short dura-
tion, and produced mixed results [33]. In a 2013 system-
atic review of 36 studies involving different interventions 
involving frail older patients in various settings, 22 of 
26 quantitative studies reported statistically significant 
reductions in the proportions of medicines deemed un-
necessary (defined using various criteria), ranging from 
3 to 20 percentage points [34]. A more recent review of 
20 trials of pharmacist-led reviews in both inpatient and 
outpatient settings reported a small reduction in the mean 
number of prescribed medicines (–0.48, 95% confidence 
interval [CI] –0.89 to –0.07) but no effects on mortal-
ity or readmissions, although unplanned hospitalizations 
were reduced in patients with heart failure [35]. A 2012 
review of 10 controlled and 20 randomized studies 
revealed statistically significant reductions in the number 
of medicines in most of the controlled studies, although 
mixed results in the randomized studies [36]. Another 
2012 review of 10 studies of different designs concluded 
that interventions were beneficial in reducing potentially 
inappropriate prescribing and medicine-related problems 
[37]. A 2013 review of 15 studies of academic detailing of 
family physicians showed a modest decline in the number 
of medications of certain classes such as benzodiazepines 
and nonsteroidal anti-inflammatory drugs [38]. Another 
2013 review restricted to 8 randomized trials of various 
interventions involving nursing home patients suggested 
medicine-related problems were more frequently identi-
fied and resolved, together with improvement in medicine 
appropriateness [39]. In 2 randomized trials conducted in 
aged care facilities and centered on educational interven-
tions, one aimed at prescribers [40] and the other at nurs-
ing staff [41], the number of potentially harmful medicines 
and days in hospital was significantly reduced [40,41], 
combined with slower declines in health-related quality of 
life [40]. In a randomized trial, patient education provided 
through community pharmacists led to a 77% reduction in 
benzodiazepine use among chronic users at 6 months with 
no withdrawal seizures or other ill effects [42]. 
Direct Deprescribing Targeting Specific Classes of 
Medicines
The evidence base for direct patient-level deprescribing is 
more rigorous as it pertains to specific classes of medicines. 
A 2008 systematic review of 31 trials (15 randomized, 16 
observational) that withdrew a single class of medicine in 
older people demonstrated that, with appropriate patient 
selection and education coupled with careful withdrawal 
and close monitoring, antihypertensive agents, psychotro-
pic medicines, and benzodiazepines could be discontin-
ued without harm in 20% to 100% of patients, although 
psychotropics showed a high post-trial rate of recom-
mencement [43]. Another review of 9 randomized trials 
demonstrated the safety of withdrawing antipsychotic 
agents that had been used continuously for behavioural 
and psychological symptoms in more than 80% of subjects 
with dementia [44]. In an observational study, cessation of 
inappropriate antihypertensives was associated with fewer 
cardiovascular events and deaths over a 5-year follow-up 
period [45]. A recent randomized trial of statin withdrawal 
in patients with advanced illness and of whom half had a 
prognosis of less than 12 months demonstrated improved 
quality of life and no increased risk of cardiovascular events 
over the following 60 days [46].  
Direct Deprescribing Targeting All Medicines
The evidence base for direct patient-level deprescribing 
that assesses all medicines, not just specific medicine 
classes, features several high-quality observational stud-
ies and controlled trials, and subgroup findings from a 
recent comprehensive systematic review. In this review of 
132 studies, which included 56 randomized controlled 
trials [47], mortality was shown in randomized trials to 
be decreased by 38% as a result of direct (ie, patient-level) 
deprescribing interventions. However, this effect was 
not seen in studies of indirect deprescribing comprising 
mainly generic educational interventions. While space 
prevents a detailed analysis of all relevant trials, some of 
the more commonly cited sentinel studies are mentioned 
here. 
In a controlled trial involving 190 patients in aged 
care facilities, a structured approach to deprescribing 
(Good Palliative–Geriatric Practice algorithm) resulted 
in 63% of patients having, on average, 2.8 medicines 
CliniCal Review
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per patient discontinued, and was associated with a 
halving in both annual mortality and referrals to acute 
care hospitals [48]. In another prospective uncontrolled 
study, the same approach applied to a cohort of 70 
community-dwelling older patients resulted in an average 
of 4.4 medicines prescribed to 64 patients being recom-
mended for discontinuation, of which 81% were success-
fully discontinued, with 88% of patients reporting global 
improvements in health [49]. In a prospective cohort study 
of 50 older hospitalized patients receiving a median of 10 
regular medicines on admission, a formal deprescribing 
process led to the cessation of just over 1 in 3 medi-
cines by discharge, representing 4 fewer medicines per 
patient [50]. During a median follow-up period of just over 
2.5 months for 39 patients, less than 5% of ceased medi-
cines were recommenced in 3 patients for relapsing symp-
toms, with no deaths or acute presentations to hospital 
attributable to cessation of medicines. A multidisciplinary 
hospital clinic for older patients over a 3-month period 
achieved cessation of 22% of medicines in 17 patients 
without ill effect [51]. 
Two randomized studies used the Screening Tool 
of Older People’s Prescriptions (STOPP) to reduce the 
use of PIMs in older hospital inpatients [52,53]. One 
reported significantly reduced PIMs use in the interven-
tion group at discharge and 6 months post-discharge, 
no change in the rate of hospital readmission, and non-
significant reductions in falls, all cause-mortality, and 
primary care visits during the 6-month follow-up period 
[52]. The second study reported reduced PIMs use in the 
intervention group of frail older patients on discharge, 
although the proportion of people prescribed at least 1 
PIM was not altered [53]. 
Recently, a randomized trial of a deprescribing inter-
vention applied to aged care residents resulted in suc-
cessful discontinuation of 207 (59%) of 348 medicines 
targeted for deprescribing, and a mean reduction of 2 
medicines per patient at 12 months compared to none 
in controls, with no differences in mortality or hospital 
admissions [54]. The evidence for direct deprescribing is 
limited by relatively few high-quality randomized trials, 
small patient samples, short duration of follow-up, selec-
tion of specific subsets of patients, and the absence of 
comprehensive re-prescribing data and clinical outcomes.
Methods Used for Direct Deprescribing
At the level of individual patient care, various instruments 
have been developed to assist the deprescribing process. 
Screening tools or criteria such as the Beers criteria and 
STOPP tool help identify medicines more likely than not 
to be inappropriate for a given set of circumstances and 
are widely used by research pharmacists. Deprescribing 
guidelines directed at particular medications (or drug 
classes) [55], or specific patient populations [56], can iden-
tify clinical scenarios where a particular drug is likely to be 
inappropriate, and how to safely wean or discontinue it. 
However, in addition to these tools, clinicians need a 
method for identifying all medicines which may be inap-
propriate when considering the personalized context of 
individual patients, irrespective of age, co-morbidity bur-
den or mix of medicines. For example, while Beers and 
STOPP criteria can identify “medications to avoid” (such 
as potent opioids and non-steroidal anti-inflammatory 
medications), such medications account for less than 25% 
of all ADEs in older patients [57]. Commonly prescribed 
“non-Beers list” medications with proven benefits in 
many older people, such as cardiovascular medications, 
anticoagulants, and hypoglycaemic agents, are more fre-
quently implicated as a result of misuse [58]. 
In applying a more nuanced, patient-centered a 
pproach to deprescribing, structured guides comprising 
algorithms, flowcharts, or tables describe sequential steps 
in deciding which medications used by an individual 
patient should be targeted for discontinuation after due 
attention to all relevant factors. Such guides prompt 
a more systematic appraisal of all medications being 
used. In a recent review of 7 structured guides that had 
undergone some form of efficacy testing [59], the strongest 
evidence of efficacy and clinician acceptability was seen 
for the Good Palliative–Geriatric Practice algorithm [48] 
(Figure) and the CEASE protocol [29,30,50,60] (Table). 
Both have been subject to a process of development 
and refinement over months to years involving mul-
tiple clinician prescribers and pharmacists. However, 
the former was designed in nursing home settings [48] 
and then applied to a community-based population 
[49] without further validation, whereas the CEASE 
protocol has assumed different forms according to the 
needs of different settings [50,61] and has been shown 
to have face validity among a cohort of prescribers and 
pharmacists [62].  
clinical circumstances conducive to 
Deprescribing
Deprescribing should be especially considered in any 
older patient presenting with a new symptom or clinical 
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syndrome suggestive of adverse medicine effects. The 
advent of advanced or end-stage disease, terminal illness, 
dementia, extreme frailty, or full dependence on others 
for all cares marks a stage of a person’s life when lim-
ited life expectancy and changed goals of care call for a 
re-appraisal of the benefits of current medicines. Lack of 
response in controlling symptoms despite optimal adher-
ence and dosing or conversely the absence of symptoms 
for long periods of time should challenge the need for 
ongoing regular use of medicines. Similarly, the lack of 
verification, or indeed repudiation, of past diagnostic 
labels which gave rise to indications for medicines in the 
first place should prompt consideration of discontinua-
tion. Patients receiving single medicines or combinations 
of medicines, both of which are high risk, should attract 
attention [63], as should use of preventive medicines for 
scenarios associated with no increased disease risk despite 
medicine cessation (eg, ceasing alendronate after 5 years 
of treatment results in no increase in osteoporotic frac-
ture risk over the ensuing 5 years [64]; ceasing statins for 
primary prevention after a prolonged period results in 
no increase in cardiovascular events 8 years after discon-
tinuation [65]). Evidence that has emerged that strongly 
contradicts previously held beliefs as to the indications 
for certain medicines (eg, aspirin as primary prevention 
of cardiovascular disease) should lead to a higher fre-
quency of their discontinuation. Finally, medicines which 
impose demands on patients which they deem intolerable 
in terms of dietary and lifestyle restrictions, adverse side 
effects, medicine monitoring (such as warfarin), financial 
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An	evidence-based	consensus	exists	for	using	the	drug		
for	the	indication	given	in	its	current	dosing	rate,		
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Figure.	Improving	drug	therapy	in	elderly	patients—
the	 Good	 Palliative–Geriatric	 Practice	 algorithm.	
Reprinted	with	permission	from	reference	48.
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cost, or any other reason likely to result in nonadherence, 
should be considered candidates for deprescribing [25]. 
barriers to Deprescribing
The most effective strategy to reducing potentially inap-
propriate polypharmacy is for doctors to prescribe and 
patients to consume fewer medicines. Unfortunately, both 
doctors and patients often lack confidence about when 
and how to cease medicines [66–69]. In a recent system-
atic review comprised mostly of studies involving gen-
eral practitioners in primary care [66], 4 themes emerged. 
First, prescribers may be unaware of their own instances 
of inappropriate prescribing in older people until this is 
pointed out to them. Poor insight may be attributable in 
part to insufficient education in geriatric pharmacology. 
Second, clinical inertia manifesting as failure to act despite 
an awareness of PIMs may arise from deprescribing being 
viewed as a risky affair [70], with doctors fearful of provok-
ing withdrawal syndromes or disease complications, and 
damaging their reputation and relationships with patients 
or colleagues in the process. Continuing inappropriate 
medicines is reinforced by prescriber beliefs that to do so 
is a safer or kinder course of action for the patient. Third, 
self-perceptions of being ill-equipped, in terms of the nec-
essary knowledge and skills, to deprescribe appropriately 
(lack of self-efficacy) may be a barrier, even if one accepts 
the need for deprescribing. Information deficits around 
benefit-harm trade-offs of particular drugs and alternative 
treatments (both drug and non-drug), especially for older, 
frail, multi-morbid patients, contribute to the problem. 
Confidence to deprescribe is further undermined by the 
lack of clear documentation regarding reasons drugs were 
originally prescribed by other doctors, outcomes of past 
trials of discontinuation, and current patient care goals. 
Fourth, several external or logistical constraints may ham-
per deprescribing efforts such as perceived patient unwill-
ingness to deprescribe certain medicines, lack of prescriber 
time, poor remuneration, and community and professional 
attitudes toward more rather than less use of medicines. 
Deprescribing in hospital settings led by specialists ap-
pears to be no better than in general practice, although 
it has been less well studied. While an episode of acute 
inpatient care may afford an opportunity to review and 
reduce medicine lists, studies suggest the opposite occurs. 
In a New Zealand audit of 424 patients of mean age 
80 years admitted acutely to a medical unit, chronically 
administered medications increased during hospital stay 
from a mean of 6.6 to 7.7 [71]. Similarly, in an Australian 
study investigating medication changes for 1220 patients 
of mean age 81 years admitted to general medical units 
of 11 acute care hospitals, the mean number of regularly 
administered medications rose from 7.1 on admission to 
Table. The	CEASE	Deprescribing	Framework
C urrent	medicines Ascertain	all	medicines	the	patient	is	currently	taking	and	the	reasons	for	each	one	(also	termed	medication		
reconciliation)
E levated	risk Consider	the	potential	for	this	patient	to	be	harmed	by	the	medicines	being	prescribed	in	determining	required	
intensity	of	deprescribing	intervention:
-	Consider	risk	factors	such	as	total	number	of	drugs,	age,	presence	of	drugs	associated	with	high	risk		
(eg,	opiates,	benzodiazepines,	psychotropics,	anticoagulants,	hypoglycaemic	drugs,	cardiovascular	
drugs),	past	non-adherence,	multiple	prescribers,	impaired	cognition	and	poor	social	support,	sub-
stance	abuse,	mental	health	problems
A ssess Assess	each	medicine	for	its	usefulness	in	relation	to	its	risk	of	harm	by	considering:
-	Indications	for	the	drug	(is	the	continued	prescribing	of	the	drug	justified	on	the	basis	of	a	verified	diag-
nosis	and	robust	evidence	of	effectiveness	for	this	indication	in	this	patient?)
-	Effects	of	the	drug	to	date	on	the	underlying	disease	process	and/or	its	symptoms
-	Future	benefit-harm	trade-offs	in	the	context	of	life	expectancy,	time	until	benefit	(for	preventive	medica-
tions),	goals	of	care	(symptom	relief	vs	disease	modification	vs	cure),	and	patient	values	and	prefer-
ences
S	ort Prioritize	those	medicines	for	discontinuation	with	lowest	utility	(or	highest	disutility)		and	greatest	ease	of	dis-
continuation,	while	taking	patient	preferences	into	account
E	liminate Implement	a	discontinuation	regimen	and	monitor	patients	closely	for	improvement	in	outcomes	or	onset	of	
withdrawal	or	rebound	syndromes
Adapted	from	references	29,	30,	and	50.
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7.6 at discharge [72]. It is likely the same drivers behind 
failure to deprescribe in primary care also operate in sec-
ondary and tertiary care settings. Part of the problem is 
under-recognition of medicine-related geriatric syndromes 
on the part of hospital physicians and pharmacists [73]. 
Patients in both the community and residential aged 
care facilities frequently express a desire to have their 
medicines reduced in number, especially if advised by 
their treating clinician [74,75]. Having said this, many 
remain wary of discontinuing specific medicines [67], 
sharing the same fears of evoking withdrawal syndromes 
or disease relapse as do prescribers, and recounting the 
strong advice of past specialists to never withhold any 
medicines without first seeking their advice. 
A challenge for all involved in deprescribing is gaining 
agreement on what are the most important factors that 
determine when, how, and in whom deprescribing should 
be conducted. Recent qualitative studies suggest that 
doctors, pharmacists, nursing staff, and patients and their 
families, while in broad agreement that deprescribing is 
worthwhile, often differ in their perspectives on what 
takes priority in selecting medicines for deprescribing in 
individual patients, and how it should be done and by 
whom [76,77].  
strategies that May Facilitate Deprescribing 
While deprescribing presents some challenges, there are 
several strategies that can facilitate it at both the level of 
individual clinical encounters and at the level of whole 
populations and systems of care. 
Individual Clinical Encounters
Within individual clinician–patient encounters, patients 
should be empowered to ask their doctors and pharma-
cists the following questions: 
•	 What	are	my	treatment	options	(including	non-
medicine options) for my condition?
•	 What	are	the	possible	benefits	and	harms	of	each	
medicine?
•	 What	might	be	reasonable	grounds	for	stopping	a	
medicine?
In turn, doctors and pharmacists should ask in a 
nonjudgmental fashion, at every encounter, whether 
patients are experiencing any side effects, administration 
and monitoring problems, or other barriers to adherence 
associated with any of their medicines. 
The issue of deprescribing should be framed as an 
attempt to alleviate symptoms (of drug toxicity), improve 
quality of life (from drug-induced disability), and lessen 
the risk of morbid events (especially ADEs) in the future. 
Compelling evidence that identifies circumstances in 
which medicines can be safely withdrawn while reducing 
the risk of ADEs needs to be emphasized. Specialists must 
play a sentinel leadership role in advising and author- 
izing other health professionals to deprescribe in situa-
tions where benefits of medications they have prescribed 
are no longer outweighed by the harms [60,78]. 
In language they can understand, patients should be 
informed of the benefit–harm trade-offs specific to them 
of continuing or discontinuing a particular medicine, as 
far as these can be specified. Patients often overestimate 
the benefits and underestimate the harms of treatments 
[79]. Providing such personalised information can sub-
stantially alter perceptions of risk and change attitudes 
towards discontinuation [80]. Eliciting patients’ beliefs 
about the necessity for each individual medicine and 
spending time, using an empathic manner, to dispel or 
qualify those at odds with evidence and clinical judge-
ment renders deprescribing more acceptable to patients. 
In estimating treatment benefit–harm trade-offs 
in individual patients, disease risk prediction tools 
(http://www.medal.org/), evidence tables [81,82], and 
decision aids are increasingly available. Prognostication 
tools (http://eprognosis.ucsf.edu) combined with trial-
based time-to-event data can be used to determine if 
medicine-specific time until benefit exceeds remaining 
life span. 
Deprescribing is best performed by reducing medi-
cines one at a time over several encounters with the same 
overseeing generalist clinician with whom patients have 
established a trusting and collaborative relationship. This 
provides repeated opportunities to discuss and assuage any 
fears of discontinuing a medicine, and to adjust the depre-
scribing plan according to changes in clinical circumstanc-
es and revised treatment goals. Practice-based pharmacists 
can review patients’ medicine lists and apply screening 
criteria to identify medicines more likely to be unnecessary 
or harmful, which then helps initiate and guide deprescrib-
ing. Integrating a structured deprescribing protocol—and 
reminders to use it—into electronic health records, and 
providing decision support and data collection for future 
reference, reduce the cognitive burden on prescribers [83]. 
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Practical guidance in how to safely wean and cease par-
ticular classes of medicines in older people can be accessed 
from various sources [84,85]. Seeking input from clinical 
pharmacologists, pharmacists, nurses, and other salient 
care providers on a case-by-case basis in the form of inter-
active case conferences provides support, seeks consensus, 
and shares the risk and responsibility for deprescribing 
recommendations [86]. 
System of Care 
The success of deprescribing efforts in realizing better 
population health will be compromised unless all key 
stakeholders involved in quality use of medicines com-
mit to operationalizing deprescribing strategies at the 
system of care level. Position statements on deprescribing 
in multi-morbid populations should be formulated and 
promulgated by all professional societies of prescribers 
(primary care, specialists, pharmacists, dentists, nurse 
practitioners). Professional development programs as well 
as undergraduate, graduate, and postgraduate courses in 
medicine, pharmacy, and nursing should include training 
in deprescribing as a core curricular element. 
Researchers seeking funding and/or ethics approval 
for research projects involving medicines should be 
required to collect, analyze, and report data on the fre-
quency of, and reasons for, withdrawal of drugs in trial 
subjects. This helps build the evidence base of medicine-
related harm. In turn, government funders of research 
should require more researchers to design and conduct 
clinical trials that recruit multi-morbid patients, includ-
ing specific subgroups (eg, patients with dementia), and 
aim to define medicine benefits and harms using patient 
risk stratification methods. Pharmaceutical companies 
should sponsor research on how to deprescribe their 
medicines within trials that also aim to assess efficacy 
and safety. Medicine regulatory authorities such as the 
Food and Drug Administration should mandate that 
this information be supplied at the time the company 
submits their application to have the medicine approved 
and listed for public subsidy. Trialists should adopt the 
word “deprescribing” in abstract titles for research on 
prescriber-initiated medicine discontinuation so that 
relevant articles can be more accurately indexed in, 
and retrieved from, bibliographic databases using re-
cently formulated medical subject headings in Medline 
(“depresciptions”). 
Editors of medical journals should promote a depre-
scribing agenda as a quality and safety issue for patient 
care, with the “Less is More” series in JAMA Internal 
Medicine and “Too much medicine” series in BMJ being 
good examples. Clinical guideline developers should for-
mulate treatment recommendations specific to the needs 
of multi-morbid patients which acknowledge the limited 
evidence base for many medicines in such populations. 
These should take account of commonly encountered 
clinical scenarios where disease-specific medicines may 
engender greater risk of harm, and provide cautionary 
notes regarding initiation and discontinuation of medi-
cines associated with high-risk. 
Pharmacists need to instruct patients in how to iden-
tify medicine-induced harm and side effects, and how 
to collaborate with their prescribing clinicians in safely 
discontinuing high-risk medicines. Ideally, patients being 
admitted to residential aged care facilities should have 
their medicine lists reviewed by a pharmacist in flagging 
medicines eligible for deprescribing. Organizations and 
services responsible for providing quality use of medi-
cines information (medicines handbooks, prescribing 
guidelines, drug safety bulletins) should describe when 
and how deprescribing should be performed in regards 
to specific medicines. This information should be cross-
referenced to clinical guidelines and position statements 
dealing with the same medicine. Vendors of medicine 
prescribing software should be encouraged to incorpo-
rate flags and alerts which prompt prescribers to consider 
medicine cessation in high-risk patients. 
Government and statutory bodies with responsibility 
for health care (health departments, quality and safety 
commissions, practice accreditation services, health care 
standard–setting bodies) should fund more research to 
develop and evaluate medicine safety standards aimed at 
reducing inappropriate use of medicines. Accreditation 
procedures for hospitals and primary care organizations 
should mandate the adoption of professional develop-
ment and quality measurement systems that support and 
monitor patients receiving multiple medicines. Organiza-
tions responsible for conducting pharmacovigilance stud-
ies should issue medicine-specific deprescribing alerts 
whenever their data suggest higher than expected inci-
dence of medicine-related adverse events in older popula-
tions receiving such medicines. 
conclusion
Inappropriate medicine use and polypharmacy is a grow-
ing issue among older and multi-morbid patients. The 
cumulative evidence of the safety and benefits of depre-
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scribing argues for its adoption on the part of all pre-
scribers, as well as its support by pharmacists and others 
responsible for optimizing use of medicines. Widespread 
implementation within routine care of an evidence-
based approach to deprescribing in all patients receiving 
polypharmacy has its challenges, but also considerable 
potential to relieve unnecessary suffering and disability. 
More high quality research is needed in defining the cir-
cumstances under which deprescribing confers maximal 
benefit in terms of improved clinical outcomes.
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